Search Results

21 - 30 of 82 items :

  • pharmacokinetics x
  • Life Sciences x
Clear All
SRC kinase mrna transcription changes in testosterone-induced rat ventral prostate lobes under the influence of epilobium angustifolium extract

prostate cancer. J Urol 2008; 179:1235-42. 33. Aggarwal S, Thareja S, Verma A, Bhardwaj TR, Kumar M. An overview on 5-α-reductase inhibitors. Steroids 2010; 75:109-153. 34. Azzouni F. Mohler J. Role of 5α-reductase inhibitors in prostate cancer prevention and treatment. Urology 2012; 79(6):1197-205. 35. Gisleskog PO, Hermann D, Hammarlund-Udenaes M, Karlsson MO. The pharmacokinetic modelling of GI198745 (dutasteride), a compound with parallel linear and nonlinear elimination. Br J Clin Pharmacol 1999; 47

Open access
Comparison of albendazole cytotoxicity in terms of metabolite formation in four model systems

non-clinical toxicity and pharmacokinetics. Acta Trop 2003, 86, 141-159. 10. Delatour P., Benoit E., Besse S., Boukraa A.: Comparative enantioselectivity in the sulphoxidation of albendazole in man, dogs, and rats. Xenobiotica 1991, 21, 217-221. 11. Delatour P., Benoit E., Caude M., Tambute A.: Species differences in the generation of the chiral sulfoxide metabolite of albendazole in sheep and rats. Chirality 1990, 2, 156-160. 12. Delatour P.: Some aspects of the teratogenicity of veterinary drugs. Vet Res Commun 1983

Open access
Successful Treatment with Triple Therapy of Amphotericin B, Voriconazole and Flucytosine on an AIDS Patients with Severe Cryptococcal Meningitis

. Efficacy of voriconazole in a murine model of cryptococcal central nervous system infection. J Antimicrob Chemother 2007;60:162-165. 4 Pfaller MA, Messer SA, Boyken L, Rice C, Tendolkar S, Hollis RJ, et al. Global trends in the antifungal susceptibility of Cryptococcus neoformans (1990 to 2004). J Clin Microbiol 2005;43: 2163-2167. 5 Liu P, Foster G, LaBadie RR, Gutierrez MJ, Sharma A. Pharmacokinetic interaction between voriconazole and efavirenz at steady state in healthy male subjects. J Clin Pharmacol 2008;48:73-84. 6

Open access
The Paradox of Human Equivalent Dose Formula: A Canonical Case Study of Abrus Precatorius Aqueous Leaf Extract in Monogastric Animals

alpha-helix H impairs protein synthesis inhibitory activity. J. Biol. Chem. 275 (3): 1897-1901. PMid:10636890 32. Mann, A., Gbate, M., Nda, Umar, A. (2003). Medicinal and economic plants of Nupeland. Bida: Jube Evans Books and Publications, p.191. 33. Mordent, J. (1986). Man versus beast: pharmacokinetic scaling in mammals. J. pharmaceut. Sci.75, 1028 – 1040. 34. Premanand, R., Ganesh, T. (2010). Neuroprotective effects of Abrus precatorius Linn. Aerial extract on

Open access
Effects of Tetracycline on Ruminal Activity and Blood Calcium in Sheep

REFERENCES 1. Agwuh, K. N., MacGowan, A., 2006: Pharmacokinetics and pharmacodynamics of the tetracyclines including glycylcyclines. J. Antimicrob. Chemotherapy , 58, 256—265. 2. Attebery, J. T., Johnson, H. D., 1969: Effects of environmental temperature, controlled feeding and fasting on rumen motility. J. Anim. Sci. , 29, 734—737. 3. Bengtsson, B., Franklin, A., Luthman, J., Jacobsson, S. O., 1989: Concentrations of sulphadimidine, oxytetracycline and penicillin G in serum, synovial fluid and tissue cage fluid after parenteral

Open access
Effect of therapeutic doses of enrofloxacin on circulating lymphocyte subpopulations in pigs

-60. 23. Vancutsem P.M., Babish J.G., Schwark W.S.: The fluoroquinolone antimicrobials: structure, antimicrobial activity, pharmacokinetics, clinical use in domestic animals and toxicity. Cornell Vet 1990, 80, 173-186. 24. Williams A.C., Galley H.F., Watt A.M., Webster N.R.: Differential effects of three antibiotics on T helper cell cytokine expression. J Antimicrob Chemother 2005, 56, 502-506. 25. Ziółkowski H., Jaroszewski J.J., Maślanka T., Grabowski T., Katolik K., Pawęska J., Siemianowska M., Jasiecka A., Markiewicz W., Spodniewska A

Open access
Influence of epilobium angustifolium extract on 5α-reductase type 2 and mapk3 kinase gene expression in rats prostates

Mol Biol 1997; 61:55-64. 41. Kang DI, Chung JL. Current status of 5α-reductase inhibitors in prostate disease management. Korean J Urol 2013; 54(4):213-9. 42. Gisleskog PO, Hermann D, Hammarlund-Udenaes M, Karlsson MO. The pharmacokinetic modelling of GI198745 (dutasteride), a compound with parallel linear and nonlinear elimination. Br J Clin Pharmacol 1999; 47:53-8. 43. Stuart JD, Lee FW, Simpson Noel D, Kadwell SH, Overton LK, Hoffman CR, Kost TA, Tippin TK, Yeager RL, Batchelor KW, Bramson HN. Pharmacokinetic

Open access
Light and Transmission Electron Microscopical Changes Associated with Leiurus Quinqestriatus Venom in Rabbits

lung mechanics and inflammation in mice. Toxicon. 53 (7 - 8): 779 - 785. 8. Nunan, E. A., Arya, V., Hochhaus, G., Cardoso, V. N., Moraes-Santos, T. (2004). Age effects on the pharmacokinetics of tityustoxin from Tityus serrulatus scorpion venom in rats. Braz. J. Med. Biol. Res. 37, 385 – 390. PMid:15060708 9. Carvalho, F. F., Nencioni, A. L., Lebrun, I., Sandoval, M. R., Dorce, V. A. (1998). Behavioral, electroencephalographic, and histopathologic effects of a neuropeptide isolated from Tityus serrulatus

Open access
Observation of Physiological Changes after Detomidine Administration in Pateri Goat

REFERENCES 1. Grimsrud, K. N., Mama, K. R., Thomasy, S. M., Stanley S. D. (2009). Pharmacokinetics of detomidine and its metabolites following intravenous and intramuscular administration in horses. Equine Vet J. 41 (4): 361-365. PMid:19562897 2. Mama, K. R., Grimsrud, K., Snell, T., Stanley, S. (2009). Plasma concentrations, behavioural and physiological effects following intravenous and intramuscular detomidine in horses. Equine Vet J. 41 (8): 772-777. 3. Hall, L.W., Clarke, K.W. (1991). Veterinary

Open access
Exenatide QW – New Perspectives 5 Years after its First Use

receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis. Diabetes Obes Metab 19: 524-536, 2017. 7. Malone J, Trautmann M, Wilhelm K, Taylor K, Kendall DM. Exenatide once weekly for the treatment of type 2 diabetes. Expert Opin Investig Drugs 18:359-367, 2009. 8. Knop FK, Brønden A, Vilsbøll T. Exenatide: pharmacokinetics, clinical use, and future directions. Expert Opin Pharmacother 18: 555-571, 2017. 9. Abd El Aziz MS, Kahle M, Meier JJ, Nauck MA. A meta-analysis comparing clinical effects of short- or

Open access